215 related articles for article (PubMed ID: 17662376)
1. Why overall survival should not be the sole valid primary endpoint of phase 3 ovarian cancer chemotherapy trials.
Markman M
Gynecol Oncol; 2007 Aug; 106(2):279-81. PubMed ID: 17662376
[No Abstract] [Full Text] [Related]
2. Re: Dr. Markman's editorial "Why overall survival should not be the sole valid primary endpoint of phase 3 ovarian cancer chemotherapy trials" Gynecol. Oncol. 106(2); 279-81: 2007.
Patsner B
Gynecol Oncol; 2008 Jan; 108(1):254-5; author reply 255. PubMed ID: 17963827
[No Abstract] [Full Text] [Related]
3. Effects of cancer drugs on survival: often poorly evaluated.
Prescrire Int; 2009 Aug; 18(102):180-3. PubMed ID: 19746577
[TBL] [Abstract][Full Text] [Related]
4. Role of intraperitoneal chemotherapy in the front-line setting.
Markman M
J Clin Oncol; 2003 May; 21(10 Suppl):145s-148s. PubMed ID: 12743130
[TBL] [Abstract][Full Text] [Related]
5. Early average change in tumor size in a phase 2 trial: efficient endpoint or false promise?
Rubinstein LV; Dancey JE; Korn EL; Smith MA; Wright JJ
J Natl Cancer Inst; 2007 Oct; 99(19):1422-3. PubMed ID: 17895470
[No Abstract] [Full Text] [Related]
6. Incremental advance or seismic shift? The need to raise the bar of efficacy for drug approval.
Sobrero A; Bruzzi P
J Clin Oncol; 2009 Dec; 27(35):5868-73. PubMed ID: 19826122
[No Abstract] [Full Text] [Related]
7. Design and endpoints of clinical trials in hepatocellular carcinoma.
Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
[TBL] [Abstract][Full Text] [Related]
8. Contemporary phase III clinical trial endpoints in advanced ovarian cancer: assessing the pros and cons of objective response rate, progression-free survival, and overall survival.
Tate Thigpen J
Gynecol Oncol; 2015 Jan; 136(1):121-9. PubMed ID: 25455732
[TBL] [Abstract][Full Text] [Related]
9. [Current topic of intraperitoneal infusions for treatment of ovarian cancer].
Fujiwara K
Gan To Kagaku Ryoho; 2008 Feb; 35(2):224-227. PubMed ID: 18372511
[No Abstract] [Full Text] [Related]
10. Intraperitoneal chemotherapy for ovarian cancer: overview and perspective.
Rao G; Crispens M; Rothenberg ML
J Clin Oncol; 2007 Jul; 25(20):2867-72. PubMed ID: 17617517
[TBL] [Abstract][Full Text] [Related]
11. Interim futility analysis with intermediate endpoints.
Goldman B; LeBlanc M; Crowley J
Clin Trials; 2008; 5(1):14-22. PubMed ID: 18283075
[TBL] [Abstract][Full Text] [Related]
12. Is single-agent chemotherapy acceptable in platinum-sensitive relapsed ovarian cancer?
Abou-Jawde RM; Oberoi SS
J Clin Oncol; 2008 May; 26(15):2602-3; author reply 2603. PubMed ID: 18487582
[No Abstract] [Full Text] [Related]
13. Novel endpoints in phase III clinical trials.
Sargent DJ
Clin Adv Hematol Oncol; 2005 Jan; 3(1):21-3. PubMed ID: 16166962
[No Abstract] [Full Text] [Related]
14. Does the Prentice criterion validate surrogate endpoints?
Berger VW
Stat Med; 2004 May; 23(10):1571-8. PubMed ID: 15122737
[TBL] [Abstract][Full Text] [Related]
15. The ethics of early stopping rules: who is protecting whom?
Cannistra SA
J Clin Oncol; 2004 May; 22(9):1542-5. PubMed ID: 15117977
[No Abstract] [Full Text] [Related]
16. Interim analyses in clinical trials: why do we plan them?
Fossâ SD; Skovlund E
J Clin Oncol; 2000 Dec; 18(24):4007-8. PubMed ID: 11118460
[No Abstract] [Full Text] [Related]
17. Intraperitoneal therapy for ovarian cancer: a treatment ready for prime time.
Armstrong DK; Brady MF
J Clin Oncol; 2006 Oct; 24(28):4531-3. PubMed ID: 17008690
[No Abstract] [Full Text] [Related]
18. Randomized phase II trials: misleading and unreliable.
Stewart DJ
J Clin Oncol; 2010 Nov; 28(31):e649-50; author reply e651-3. PubMed ID: 20855829
[No Abstract] [Full Text] [Related]
19. [Intraperitoneal chemotherapy for ovarian cancer].
Noma J; Yoshida N
Gan To Kagaku Ryoho; 2008 Jun; 35(6):885-90. PubMed ID: 18633214
[TBL] [Abstract][Full Text] [Related]
20. Clinical trials of novel and targeted therapies: endpoints, trial design, and analysis.
Suman VJ; Dueck A; Sargent DJ
Cancer Invest; 2008 Jun; 26(5):439-44. PubMed ID: 18568764
[No Abstract] [Full Text] [Related]
[Next] [New Search]
